

AUTHOR INDEX Volume 29 January - June 1984

- Abdel Wareth, A.A., 535
- Aedo, A.-R., 1
- Ahsan, R.K., 45
- Albar, E., 55
- Alton, K.B., 19
- Asch, R.H., 83
- Baker, D.A., 519
- Balmaceda, J.P., 83
- Bank, H., 65
- Bapat, B.V., 367
- Baras, M., 203
- Barbosa, I., 197
- Bardin, C.W., 271, 283
- Barr, K.J., 291
- Beier, S., 345
- Bhattacharya, K., 385
- Blais, P., 527
- Borghì, M.R., 83
- Buckshee, K., 75
- Burgos, L., 83
- Bye, P.G., 325
- Bygdeman, M., 399, 423, 457
- Carreira, C., 197
- Chan, G.L., 359
- Chan, W.Y., 91
- Chasseaud, L.F., 375
- Chaudhuri, C., 573
- Christensen, N.J., 423, 457
- Chumrijarakij, T., 241
- Coutinho, E.M., 197
- Crona, N., 261
- Diczfalusy, E., 1, 437
- Dubin, N.H., 553, 561
- Dubois, M., 305
- Dusterberg, B., 345
- Duvivier, J., 305
- Elder, M.G., 325, 447
- El Sokkary, H., 181
- Eneroth, P., 465
- Farooq, A., 45
- Felding, C., 251
- Fleetwood, L., 465
- Forrest, M.E., 375
- Fotherby, K., 325, 447
- Franchimont, P., 305
- Fu, W.O., 471
- Gaspard, U.J., 305
- Ghodgaonkar, R.B., 553, 561
- Gillain, D., 305
- Goh, T.H., 359
- Gomaa, A.A., 535
- Hamawi, A., 325
- Hanafiah, M.J., 55
- Hariharan, M., 359
- Harlap, S., 203
- Haspels, A.A., 495
- Hertz, R., 107
- Hetyei, N.S., 19
- Homonnai, Z.T., 189, 479, 543
- Horbelt, D.V., 215
- Howard, G., 325, 447
- Johannisson, E., 1
- John, B.A., 375
- Kaban, R.M., 55
- Kabir, S.N., 385
- Kajanoja, P., 251
- Kapur, M.M., 45
- King, T.M., 553, 561
- Klove, K.L., 319
- Kovacs, L., 399
- Kurunmaki, H., 31, 411
- Kurz, K.H., 495
- Lähteenmäki, P.L.A., 31, 411
- Lan, P.T., 1
- Landgren, B.-M., 1, 437, 465
- Laumas, K.R., 45
- Li-Juan, Q., 229
- Lobo, R.A., 319
- Lumbanraja, M., 55
- Lun, K.C., 55
- Luukkainen, T., 31, 411
- MacDonald, M., 65
- Magidpr, S., 203
- Mäkilä, U.M., 251
- Mandelin, M., 251
- Medhat, M., 181
- Mhaskar, A., 75
- Mokkapati, S., 45
- Muggeridge, J., 447
- Mukherjea, M., 573
- Nandedkar, T.D., 367
- Olund, A., 251

CONTRACEPTION

- Onthuam, Y., 241
 Osman, F.H., 535
 Osman, M., 181
 Pakrash, A., 385
 Pal, A.K., 385
 Palti, H., 203
 Parmley, T.H., 553, 561
 Patrick, J.E., 19
 Pauerstein, C.J., 83
 Paz, G.F., 189, 479, 543
 Pedersen, H., 251
 Qui, J.P., 471
 Rahman, H.A., 181
 Resch, B.A., 399
 Rivier, J., 271
 Roberts, D.K., 215
 Rosén, A.-S., 423
 Rosenshein, N.B., 561
 Rowe, R.J., 399
 Roy, S., 319
 Salah, M., 335
 Salem, H.I., 535
 Samsioe, G., 261
 Sas, M., 399
 Schally, A.V., 83
 Schmidt, F., 271, 283
 Shaaban, M.M., 335
 Shaw, C., 19
 Sheth, A.R., 367
 Shih, S., 229
 Shilon, M., 189, 479
 Silberstolpe, G., 261
 Silva, A.R., 197
 Simanjuntak, P., 55
 Sitompul, H., 55
 Smith, M., 527
 Somell, C., 251
 Sørensen, S.S., 171
 Souka, A.R., 181
 Strandberg, J.D., 561
 Stumpf, P.G., 511
 Sundaram, K., 163, 271, 283
 Sunyavivat, S., 241
 Swahn, M.L., 399
 Tadesse, E., 495
 Talwar, G.P., 75
 Tam, P.P.L., 91
 Thau, R.B., 143, 271, 283
 Thomas, J., 519
 Toivonen, J., 31, 411
 Udomprasertgul, V., 241
 Ugocsai, M.L., 399
 Vale, W., 271
 van de Wiel, J.A.C., 375
 von Knorring, K., 423
 Walker, N.J., 215
 Wiebe, J.P., 291
 Wiechert, S., 65
 Wolf, P., 171
 Wong, P.Y.D., 471
 Wood, S.G., 375
 Xuan, L., 229
 Yeung, H.W., 91
 Ylikorkaia, O., 251
 Yong-En, S., 447

SUBJECT INDEX Volume 29 January - June 1984

- A Quest for Better Contraception: the Ford Foundation's contribution to reproductive science and contraceptive development 1959-1983, 107
- Abortifacient activity, α -momorcharin and β -momorcharin (mouse), 91
- Abortion rate,
 - intraamniotic instillation of PGF_{2 α} , 171
 - intracervical administration of PGE₂ gel, 171
- [Ac-D-NAL(2)¹,4FD-Phe^{2D},-Trp³,D-Arg⁶]-LHRH,
 - acute toxicity studies (mouse, rat, rabbit, monkey), 283
 - produces transient edema and behavioral changes (rat), 283
 - species differences in sensitivity to antitesticular effects (mouse, rat, rabbit, monkey), 271
- Acceptability,
 - phenoxybenzamine as a male contraceptive pill, 479
 - prostaglandin treatment in hospital or at home compared with vacuum aspiration for termination of early pregnancy, 423
- Acetylcholinesterase level, effect of norethisterone enanthate, 573
- Acid phosphatase level, effect of norethisterone enanthate, 573
- Age, effect on the functional length and fundus transversal of uterine cavity, 495
- Albumin content of cervical secretion, effect of copper IUDs, 465
- Alkaline phosphatase level, effect of norethisterone enanthate, 573
- Amount of wet weight mucus, effect of copper IUDs, 465
- Androstenedione level,
 - effect of ethinylestradiol + levonorgestrel, 305
 - effect of 1,2,3-trihydroxypropane (rat), 291
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
- Anemia and menstrual blood loss,
 - use of ML Cu250, 359
 - use of Progestasert (Alza I), 359
- Anthropometric measurements, follow-up of children whose mothers used oral contraceptives prior to conception, 203
- Anti-fertility effect, inhibin-enriched preparation (hamster), 367
- Antifertility effects,
 - LHRH agonists, 143, 163
 - LHRH antagonists, 143, 163
- Antigonadal effects, LHRH antagonist (mouse, rat, rabbit, monkey), 271
- Antitesticular effects, species differences in sensitivity to [Ac-D-NAL(2)¹,4FD-Phe^{2D},D-Arg⁶]-LHRH (mouse, rat, rabbit, monkey), 271
- Anti-zona activity,
 - in fertile men, 75
 - in nonpregnant fertile women, 75
 - in pregnant women, 75
 - in tubectomized women, 75
- Apo-lipoprotein AI level, effect of progestins administered alone and in combination with ethinyl estradiol, 261
- Aspirin (acetylsalicylic acid), effect on luteal phase of menstrual cycle, 181
- Associated factors contributing to contraceptive discontinuations, 241

CONTRACEPTION

- Attitudes pretreatment and post-treatment, prostaglandin treatment in hospital or at home compared with vacuum aspiration for termination of early pregnancy, 423
- Autoantibodies to zona pellucida, presence in tubectomized women, 75
- Behavioral changes, use of LHRH antagonist (mouse, rat, rabbit, monkey), 283
- Biotransformation, norgestimate, 19
- Blastocyst,
 - effect of administration of inhibin-enriched preparation (hamster), 367
 - effect of β -momorcharin (mouse), 91
- Bleeding pattern,
 - effect of levonorgestrel-releasing intracervical device, 31
 - effect of ST-1435-releasing intracervical device, 411
- Bleeding profile, effect of depot-medroxyprogesterone acetate, 1
- Blood chemistry,
 - effect of intrauterine administration of quinacrine (monkey), 561
 - effect of intrauterine administration of tetracycline and analogues (monkey), 561
- Blood loss, use of 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester prior to vacuum aspiration, 251
- Blood pressure, effect of phenoxybenzamine, 479
- Body weight,
 - effect of gossypol acetic acid (rat), 471
 - effect of LHRH antagonist (rat, rabbit), 271
 - effect of phenoxybenzamine hydrochloride (rat), 189
- Cavimeter, use in measurements of uterine cavities, 495
- Cervical cap,
 - examination of used caps, 527
 - Prentif®, 527
 - Vimule®, 527
- Cervical dilatation, 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester prior to vacuum aspiration, 251, 457
- Cervical secretion content, IUD-induced changes, 465
- Children whose mothers used oral contraceptives prior to conception, long-term follow-up, 203
- Chloroquine, effect of intrauterine instillation on uterine morphology (rat), 553
- Cholesterol level, effect of progestins administered alone and in combination with ethinyl estradiol, 261
- Clinical experience,
 - levonorgestrel-releasing capsules, 335
 - TCu-380-Ag, 335
- Clinical performance,
 - levonorgestrel-releasing intracervical device, 31
 - ST-1435-releasing intracervical device, 411
- Clinical results, use of 16,16-dimethyl-trans- Δ^2 -PGE₁ methyl ester for cervical dilatation prior to vacuum aspiration, 457
- Coagulating glands, effect of phenoxybenzamine hydrochloride (rat), 189
- Comparative clinical experience, TCu 380Ag, TCu 220C and Mahua ring, 229
- Comparison of three types of tubal sterilization methods, 55
- Complaints,
 - levonorgestrel-releasing implant, 335
 - TCu-380-Ag, 335
- Complaints during operation, comparison of tubal sterilization methods, 55
- Complement C_{3c} content of cervical secretion, effect of copper IUDs, 465

- Complications,
 - intraamniotic instillation of $\text{PGF}_2\alpha$, 171
 - intracervical administration of PGE_2 gel, 171
 - prostaglandin treatment at home, 423
 - prostaglandin treatment in hospital, 423
 - use of 16,16-dimethyl-trans- Δ^2 - PGE_1 methyl ester for cervical dilatation prior to vacuum aspiration, 457
 - vacuum aspiration, 423
- Concanavalin A stimulation of lymphocytes, effect of oral contraceptives, 519
- Conception, after last injection of norethisterone oenanthate, 447
- Continuation rate,
 - levonorgestrel-releasing implant, 335
 - Mahua ring, 229
 - ICu 220C, 229
 - ICu 380Ag, 229, 335
- Contraception for women, LHRH and its analogs, 143
- Contraceptives, study on factors associated with discontinuations, 241
- Copper intravas device (monkey), 45
- Copper IUDs, effect on cervical secretion content of albumin, IgG and complement C_3C , 465
- Copper level, use of copper intravas device (monkey), 45
- Cortisol level,
 - effect of ethinylestradiol + levonorgestrel, 305
 - effect of RU 486, 399
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
- Culdoscopic ligation, comparison of tubal sterilization methods, 55
- D-Trp⁶ LH-RH, effects on menstrual cycle and endometrium (monkey), 83
- Dalkon Shield,
 - fluid migration through multifilament tail, 65
 - scanning electron microscopy of multifilament string, 215
- Dehydroepiandrosterone level,
 - effect of ethinylestradiol + levonorgestrel, 305
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
- Dehydroepiandrosterone sulfate level,
 - effect of ethinylestradiol + levonorgestrel, 305, 319
 - effect of ethinylestradiol + norethindrone, 319
 - effect of levonorgestrel implant, 319
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
- Demeclocycline, effect of intrauterine instillation on uterine morphology (rat), 543
- Demeclocycline hydrochloride, effect of intrauterine administration (monkey), 561
- Demeclocycline level, following intrauterine administration of demeclocycline (monkey), 561
- 9-Deoxo-16,16-dimethyl-9-methylene- PGE_2 , termination of early pregnancy, 423
- Depot-medroxyprogesterone acetate,
 - factors associated with discontinuations, 241
 - pharmacokinetic and pharmacodynamic study, 1
- Desogestrel, effect on apo-lipoprotein AI and SHBG, 261
- Dihydrotestosterone level,
 - effect of ethinylestradiol + levonorgestrel, 305
 - effect of triphasic ethinylestradiol + levonorgestrel, 305

CONTRACEPTION

- 16,16-Dimethyl-trans- Δ^2 -PGE₁ methyl ester,
 - cervical dilatation prior to vacuum aspiration, 457
 - vaginal suppository for cervical priming prior to termination of first trimester pregnancy, 251
- Discontinuation of contraceptives, study on associated factors, 241
- Doxycycline hydrochloride,
 - effect of intrauterine administration (monkey), 561
 - effect of intrauterine instillation on uterine morphology (rat), 553
- Doxycycline level, following intrauterine administration of doxycycline (monkey), 561
- Early pregnancy, effect of β -momorcharin (mouse), 91
- Early pregnancy termination,
 - 9-deoxo-16,16-dimethyl-9-methylene-PGE₂, 423
 - use of RU 486, 399
- Edema, use of LHRH antagonist (mouse, rat, rabbit, monkey), 283
- Endometrial appearance, effect of depot-medroxyprogesterone acetate, 1
- Endometrial development, effect of aspirin, 181
- Endometrial function, effect of depot-medroxyprogesterone acetate, 1
- Endometrial transformation, effect of repeated intravenous and subcutaneous administration of levonorgestrel (dog), 345
- Endometrium, effects of LH-RH agonist and antagonist (monkey), 83
- Epididymal sperm motility initiation, effect of gossypol acetic acid (rat), 471
- Epididymal sperm number, effect of 1,2,3-trihydroxypropane (rat), 291
- Epididymis weight,
 - effect of phenoxybenzamine hydrochloride (rat), 189
 - effect of 1,2,3-trihydroxypropane (rat), 291
- Estradiol level,
 - effect of depot-medroxyprogesterone acetate, 1
 - effect of ethinylestradiol + levonorgestrel, 305, 437
 - effect of levonorgestrel-releasing intracervical device, 31
 - effect of mestranol + norethindrone, 197
 - effect of norethisterone oenanthate, 325
 - effect of SI-1435-releasing intracervical device, 411
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
 - effects of LH-RH agonist and antagonist (monkey), 83
- Estrogen cytosol receptor concentration, effects of LH-RH agonist and antagonist (monkey), 83
- Estrone level,
 - effect of ethinylestradiol + levonorgestrel, 305
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
- Ethanol, effect on pharmacokinetics of levonorgestrel (rat), 535
- Ethanol and levonorgestrel, interaction (rat), 535
- Ethinyl estradiol, effect on apo-lipoprotein AI and SHBG, 261
- Ethinyl estradiol + desogestrel, effect on apo-lipoprotein AI and SHBG, 261
- Ethinylestradiol + levonorgestrel,
 - effect on apo-lipoprotein AI and SHBG, 261
 - effect on concentration of dehydroepiandrosterone sulfate, 319
 - effect on ovarian function, 305
 - hormonal consequences of missing the pill, 437
- Ethinylestradiol + levonorgestrel triphasic, effect on ovarian function, 305
- Ethinylestradiol + norethindrone, effect on concentration of dehydroepiandrosterone sulfate, 319

- d-13-Ethyl-17-acetoxy-18,19-dinor-17 α -pregn-4-en-20-yn-3-oxime (Norgestimate; ORF-10131),
 - biotransformation, 19
 - isolation of urinary metabolites, 19
- Excretion, intra-vaginal administration of sulphated polysaccharide (rabbit), 375
- Expulsion rate,
 - Mahua ring, 229
 - TCu 220C, 229
 - TCu 380Ag, 229
- Extrapituitary effects, LHRH agonists, 143
- Factors associated with contraceptive discontinuations, 241
- Family planning agencies, establishing medical guidelines for selecting oral contraceptive types, 511
- Fertility,
 - effect of gossypol acetic acid (rat), 471
 - effect of LHRH antagonist (rat, rabbit), 271
 - effect of phenoxybenzamine hydrochloride (rat), 189
 - effect of 1,2,3-trihydroxypropane (rat), 291
 - resumption after norethisterone oenanthate, 447
- Fertility performance, effect of copper intravas device (monkey), 45
- First trimester pregnancy termination, 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester vaginal suppository for cervical priming prior to vacuum aspiration, 251
- Fluid migration, multifilament tail of Dalkon Shield, 65
- Follow-up of children whose mothers used oral contraceptives prior to conception, 203
- Ford Foundation's contribution to reproductive science and contraceptive development 1959-1983,
 - core grants and institutional development, 107
 - Novel Approaches Program, 1975-1980, 107
 - Program for the Introduction and Adaption of Contraceptive Technology (PIACT), 107
 - program of support
 - regional and country-wide programs, 107
 - retrospect and recount, 107
 - Targeted Research Program, 1980-1983, 107
 - the Population Council's Biomedical Division and the International Committee for Contraception Research, 107
- FSH (follicle stimulating hormone or follitropin)
- FSH level,
 - effect of depot-medroxyprogesterone acetate, 1
 - effect of ethinylestradiol + levonorgestrel, 305
 - effect of levonorgestrel-releasing intracervical device, 31
 - effect of phenoxybenzamine, 479
 - effect of SI-1435-releasing intracervical device, 411
 - effect of 1,2,3-trihydroxypropane (rat), 291
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
 - effects of LH-RH agonist and antagonist (monkey), 83
- Functional length of cervix, in vivo measurements of uterine cavities with the Cavimeter, 495
- Functional length of uterine cavity, in vivo measurements using the Cavimeter, 495

CONTRACEPTION

- Fundus transversal, in vivo measurements of uterine cavities with the Cavimeter, 495
- Glucose utilization, effect of gossypol acetic acid on isolated interstitial cells (rat), 543
- Glutamate oxaloacetate transaminase level, effect of norethisterone enanthate, 573
- Glutamate pyruvate transaminase level, effect of norethisterone enanthate, 573
- Gonadotropin secretion,
 effect of ethinylestradiol + levonorgestrel, 305
 effect of triphasic ethinylestradiol + levonorgestrel, 305
- Gossypol acetic acid,
 effect on metabolism and testosterone secretion of isolated interstitial cells (rat), 543
 effect on testicular fluid secretion (rat), 471
 effects on fertility (rat), 471
- Guidelines for selecting oral contraceptive types in family planning agencies, 511
- Haemoglobin level,
 ML Cu250, 359
 Progestasert (Alza I), 359
- hCG (human chorionic gonadotropin)
 β -hCG level, effect of RU 486, 399
- Height, follow-up of children whose mothers used oral contraceptives prior to conception, 203
- Hematologic outcome, follow-up of children whose mothers used oral contraceptives prior to conception, 203
- Hematology tests,
 effect of intrauterine administration of quinacrine (monkey), 561
 effect of intrauterine administration of tetracycline and analogues (monkey), 561
- Hibiscus rosa-sinensis, potential source of contragestative agent, 385
- Hibiscus rosa-sinensis benzene extract, effect on implantation (mouse), 385
- Hormonal consequences of missing the pill, ethinyl estradiol + levonorgestrel, 437
- 17-Hydroxy-4-pregnene-3,20-dione level, effect of 1,2,3-trihydroxypropane (rat), 291
- 17 β -Hydroxy-11 β -(4-dimethylaminophenyl)-17 α -(1-propynyl)estra-4,9-dien-3-one (RU 486), termination of very early pregnancy, 399
- 20 α -Hydroxy-4-pregnene-3-one level, effect of 1,2,3-trihydroxypropane (rat), 291
- IgG content of cervical secretion, effect of copper IUDs, 465
- Immune response, effect of oral contraceptives, 519
- Implant contraceptive,
 levonorgestrel, 319
 releasing levonorgestrel, 335
- Implantation,
 effect of administration of inhibin-enriched preparation (hamster), 367
 effect of Hibiscus rosa-sinensis benzene extract (mouse), 385
- Inhibin-enriched preparation, local anti-fertility effect (hamster), 367
- Initial immune response to infection, effect of oral contraceptives, 519

- Injectable contraceptive,
 - depot-medroxyprogesterone acetate, 1, 241
 - norethisterone enanthate, 573
 - norethisterone oenanthate, 325, 447
- Interaction between levonorgestrel and ethanol (rat), 535
- Interstitial cells, effect of gossypol acetic acid on metabolism and testosterone secretion (rat), 543
- Intraamniotic PGF_{2α}, induction of second trimester abortion, 171
- Intracervical contraceptive device,
 - releasing levonorgestrel, 31
 - releasing SI-1435, 411
- Intracervical PGE₂ gel, induction of second trimester abortion, 171
- Intratesticular injection, 1,2,3-trihydroxypropane (rat), 291
- Intrauterine administration,
 - effect of quinacrine (monkey), 561
 - effect of tetracycline and analogues (monkey), 561
- Intrauterine device (IUD),
 - Dalkon Shield, 65, 215
 - factors associated with discontinuations, 241
 - Mahua ring, 229
 - ML Cu250, 359
 - Multiload, 465
 - Nova-T, 465
 - Progestasert (Alza I), 359
 - TCu 220C, 229
 - TCu 380Ag, 229, 335
- Intrauterine instillation,
 - effect of quinacrine and analogues on uterine morphology (rat), 553
 - effect of tetracycline and analogues on uterine morphology (rat), 553
- Intravas copper device and male contraception (monkey), 45
- Intravenous administration of levonorgestrel, plasma levels and progestational activity (dog), 345
- Isolated interstitial cells, effect of gossypol acetic acid on metabolism and testosterone secretion (rat), 543
- IUD (intrauterine device)
- Kidney biopsies,
 - effect of intrauterine administration of quinacrine (monkey), 561
 - effect of intrauterine administration of tetracycline and analogues (monkey), 561
- Laparoscopic tubal cautery, comparison of tubal sterilization methods, 55
- Levonorgestrel,
 - effect of ethanol on pharmacokinetics (rat), 535
 - effect on apo-lipoprotein AI and SHBG, 261
 - effect on concentration of dehydroepiandrosterone sulfate, 319
 - pharmacokinetics (dog), 345
 - plasma levels and progestational activity after repeated intravenous and subcutaneous administration (dog), 345
- Levonorgestrel and ethanol, interaction (rat), 535
- Levonorgestrel level,
 - effect of ethinyl estradiol + levonorgestrel, 437
 - interaction of ethanol with levonorgestrel (rat), 535
 - repeated intravenous and subcutaneous administration (dog), 345
 - use of levonorgestrel implant, 319
 - use of levonorgestrel-releasing intracervical device, 31

CONTRACEPTION

- Levonorgestrel-releasing implant, clinical experience, 335
- Levonorgestrel-releasing intracervical device,
 - clinical performance, 31
 - effects on pituitary and ovarian function, 31
- Leydig cell function, effects of LHRH agonists, 163
- LH (luteinizing hormone or lutropin)
- LH level
 - effect of aspirin, 181
 - effect of depot-medroxyprogesterone acetate, 1
 - effect of ethinylestadiol + levonorgestrel, 305, 437
 - effect of levonorgestrel-releasing intracervical device, 31
 - effect of LHRH antagonist (rat), 271
 - effect of phenoxybenzamine, 479
 - effect of SI-1435-releasing intracervical device, 411
 - effect of 1,2,3-trihydroxypropane (rat), 291
 - effect of triphasic ethinylestadiol + levonorgestrel, 305
 - effects of LH-RH agonist and antagonist (monkey), 83
- LHRH (luteinizing hormone-releasing hormone)
- LHRH agonist,
 - D-Trp⁶ LH-RH, 83
 - [(imBzl)-D-His⁶,Pro⁹NET]-LHRH, 283
- LHRH agonists,
 - effects on Leydig cell function, 163
 - effects of luteal function, 143
 - effects on ovulation, 143
 - effects on pituitary function, 163
 - effects on pregnancy, 143
 - effects on seminiferous tubular function, 163
 - extrapituitary effects, 143
 - inhibition of ovulation (primate), 143
 - mechanisms by which they exert antifertility effects, 143
 - pituitary mediated effects, 143
- LHRH agonists and antagonists in male contraception, 163
- LHRH agonists as antifertility agents, 143, 163
- LHRH and its agonists, induction of luteolysis (primate), 143
- LHRH and its analogs for contraception in women, 143
- LHRH antagonist,
 - [Ac-D-NAL(2)¹,4FD-Phe²,D-TRP³,Arg⁶]-LHRH, 271, 283
 - [Ac-Δ³Pro¹,4FD-Phe²,D-NAL(2)^{3,6}]-LHRH, 283
 - [Ac-Δ³Pro¹,4FD-Phe²,D-Trp^{3,6}]-LHRH, 283
 - [N-Ac-D-Trp^{1,3},D-p-Cl-Phe²,D-Arg⁶,D-Ala¹⁰]-LH-RH, 83
- LHRH antagonists, inhibition or delay of ovulation, 143
- LHRH antagonists as antifertility agents, 143, 163
- Liver biopsies,
 - effect of intrauterine administration of quinacrine (monkey), 561
 - effect of intrauterine administration of tetracycline and analogues (monkey), 561
- Liver function tests, effect of norethisterone enanthate, 573
- Luteal insufficiency, LHRH agonists, 143
- Luteal phase length and function, effect of aspirin, 181
- Luteolysis,
 - effects of LHRH agonists, 143
 - effects of LHRH and its agonists (primate), 143
- Mahua ring, clinical experience, 229

- Male contraception,
 - copper intravas device (monkey), 45
 - gossypol acetic acid (rat), 471
 - LHRH agonists and antagonists, 163
 - phenoxybenzamine, 479
 - phenoxybenzamine hydrochloride (rat), 189
- Male fertility,
 - effect of gossypol acetic acid (rat), 471
 - effect of LHRH antagonist (rat, rabbit), 271
 - effect of phenoxybenzamine hydrochloride (rat), 189
 - effect of 1,2,3-trihydroxypropane (rat), 291
- Male fertility performance, effect of copper intravas device (monkey), 45
- Mating behavior, effect of LHRH antagonist (rat, rabbit), 271
- Mating frequency, effect of 1,2,3-trihydroxypropane (rat), 291
- Measurements of uterine cavities, 495
- Medical guidelines for selecting oral contraceptive types in family planning agencies, 511
- Medroxyprogesterone acetate level, after administration of depot-medroxyprogesterone acetate, 1
- Menstrual blood loss and anemia,
 - use of ML Cu250, 359
 - use of Progestasert (Alza I), 359
- Menstrual cycle,
 - effect of aspirin, 181
 - effects of LH-RH agonist and antagonist (monkey), 83
- Mestranol + norethindrone, ovulation inhibition following vaginal administration of pills, 197
- Metabolism,
 - effect of gossypol acetic acid on isolated interstitial cells (rat), 543
 - norgestimate, 19
- Metabolites of norgestimate, 19
- 16-Methylene-17 α -acetoxy-19-nor-4-pregnene-3,20-dione (SI-1435),
 - intracervical contraceptive device, 411
- Migration of fluid, multifilament tail of Dalkon Shield, 65
- Minilaparotomy, comparison of tubal sterilization methods, 55
- Missing the contraceptive pill, hormonal consequences, 437
- ML Cu250, anemia and menstrual blood loss, 359
- β -Momorcharin,
 - properties, 91
 - termination of early pregnancy (mouse), 91
- Mortality,
 - effect of intrauterine quinacrine and related drugs (rat), 553
 - effect of intrauterine tetracycline and related drugs (rat), 553
- Multifilament IUD string,
 - fluid migration, 65
 - scanning electron microscopy, 215
- Multiload, effect on cervical secretion content of albumin, IgG and complement C3c, 465
- [N-Ac-D-Trp^{1,3}, D-p-Cl-Phe², D-Arg⁶, D-Ala¹⁰]-LH-RH, effects on menstrual cycle and endometrium (monkey), 83
- Norethisterone enanthate, studies on some enzymes and sialic acid, 573
- Norethisterone level, after administration of norethisterone oenanthate, 447

CONTRACEPTION

- Norethisterone oenanthate,
 - pharmacokinetics, 325
 - return of ovulation and fertility, 447
- Norgestimate (DRF-10131; d-13-ethyl-17-acetoxy-18,19-dinor-17 α -pregn-4-en-20-yn-3-oxime),
- Nova-T, effect on cervical secretion content of albumin, IgG and complement C_{3c}, 465
- Oestradiol level, effect of norethisterone oenanthate, 447
- Oral contraceptive,
 - desogestrel, 261
 - ethinyl estradiol, 261
 - ethinyl estradiol + desogestrel, 261
 - ethinyl estradiol + levonorgestrel, 261,305,319,437
 - ethinylestradiol + norethindrone, 319
 - levonorgestrel, 261
 - triphasic ethinylestradiol + levonorgestrel, 305
- Oral contraceptive types, establishing medical guidelines for selection in family planning agencies, 511
- Oral contraceptive use prior to conception, follow-up of children, 203
- Oral contraceptives,
 - effect on initial immune response to infection, 519
 - factors associated with discontinuations, 241
- Outcome of therapy,
 - prostaglandin treatment at home, 423
 - prostaglandin treatment in hospital, 423
 - RU 486 for termination of very early pregnancy, 399
 - vacuum aspiration, 423
- Ovarian function,
 - effect of depot-medroxyprogesterone acetate, 1
 - effect of ethinylestradiol + levonorgestrel, 305
 - effect of levonorgestrel-releasing intracervical device, 31
 - effect of norethisterone oenanthate, 325
 - effect of SI-1435-releasing intracervical device, 411
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
 - return of activity after discontinuing norethisterone oenanthate, 447
- Ovarian reaction, consequence of missing the pill, 437
- Ovulation,
 - effect of LHRH antagonists, 143
 - effects of LH-RH agonist and antagonist (monkey), 83
 - resumption after norethisterone oenanthate, 447
 - return after depot-medroxyprogesterone acetate, 1
- Ovulation inhibition,
 - LHRH agonists, 143
 - LHRH agonists (primate), 143
 - vaginal administration of pills containing mestranol + norethindrone, 197
- Oxygen consumption, effect of gossypol acetic acid on isolated interstitial cells (rat), 543
- Parity, effect on functional length and fundus transversal of uterine cavity, 495
- PG (prostaglandin)
- PGE₂ gel intracervically administered, second trimester abortion, 171
- PGF_{2 α} intraamniotic instillation, second trimester abortion, 171
- Pharmacokinetic and pharmacodynamic study, depot-medroxyprogesterone acetate, 1

- Pharmacokinetic parameters,
 - effect of interaction between levonorgestrel and ethanol (rat), 535
 - repeated intravenous and subcutaneous administration of levonorgestrel (dog), 345
- Pharmacokinetics,
 - different doses of norethisterone oenanthate, 325
 - levonorgestrel (dog), 345
- Phenoxybenzamine (N-phenoxyisopropyl-N-benzyl- β -chloroethylamine), use as a male contraceptive pill, 479
- Phenoxybenzamine hydrochloride, use as a male contraceptive drug (rat), 189
- Phospholipids level, effect of progestins administered alone and in combination with ethinyl estradiol, 261
- Pituitary function,
 - effect of levonorgestrel-releasing intracervical device, 31
 - effect of SI-1435-releasing intracervical device, 411
 - effects of LHRH agonists, 163
- Pituitary mediated effects, LHRH agonists, 143
- Plasma level, intra-vaginal administration of sulphated polysaccharide (rabbit), 375
- Pokeweed mitogen stimulation of lymphocytes, effect of oral contraceptives, 519
- Post-operative complications, comparison of tubal sterilization methods, 55
- Post-operative pregnancy, comparison of tubal sterilization methods, 55
- Potassium concentration in secreted testicular fluid, effect of gossypol acetic acid (rat), 471
- Pregnancy interruption, LHRH agonists, 143
- Pregnancy rate,
 - Mahua ring, 229
 - ICu 220C, 229
 - ICu 380Ag, 229
- Pregnancy termination, effect of β -momorcharin (mouse), 91
- Pregnanediol-3 α -glucuronide level, effect of aspirin, 181
- Prentif[®],
 - examination of used caps, 527
 - potential sites for problems on the cap, 527
- Primaquine, effect of intrauterine instillation on uterine morphology (rat), 553
- Progestasert (Alza I), anemia and menstrual blood loss, 359
- Progestational activity, repeated intravenous and subcutaneous administration of levonorgestrel (dog), 345
- Progesterone cytosol receptor concentration, effects of LH-RH agonist and antagonist (monkey), 83
- Progesterone level,
 - effect of depot-medroxyprogesterone acetate, 1
 - effect of ethinylestradiol + levonorgestrel, 305, 437
 - effect of levonorgestrel-releasing intracervical device, 31
 - effect of mestranol + norethindrone, 197
 - effect of norethisterone oenanthate, 325, 447
 - effect of RU 486, 399
 - effect of SI-1435-releasing intracervical device, 411
 - effect of 1,2,3-trihydroxypropane (rat), 291
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
 - effects of LH-RH agonist and antagonist (monkey), 83

CONTRACEPTION

- Prolactin level,
 - effect of depot-medroxyprogesterone acetate, 1
 - effect of ethinylestradiol + levonorgestrel, 305
 - effect of phenoxybenzamine, 479
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
- Prostaglandin (PG),
 - 9-deoxo-16,16-dimethyl-9-methylene-PGE₂, 423
 - 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester, 251, 457
 - PGE₂, 171
 - PGF_{2 α} , 171
- Prostaglandin treatment in hospital or at home compared with vacuum aspiration, termination of early pregnancy, 423
- Prostate weight,
 - effect of phenoxybenzamine hydrochloride (rat), 189
 - effect of 1,2,3-trihydroxypropane (rat), 291
- Psychometric tests, follow-up of children whose mothers used oral contraceptives prior to conception, 203
- Quinacrine hydrochloride,
 - effect of intrauterine administration (monkey), 561
 - effect of intrauterine instillation on uterine morphology (rat), 553
- Quinacrine level, following intrauterine administration of quinacrine (monkey), 561
- Randomized trial, intracervical PGE₂ gel and intraamniotic PGF_{2 α} for induction of second trimester abortion, 171
- Recovery profile, used cervical caps, 527
- Removals,
 - Mahua ring, 229
 - ICu 220C, 229
 - ICu 380Ag, 229
- Reproductive tissue,
 - effect of intrauterine administration of quinacrine (monkey), 561
 - effect of intrauterine administration of tetracycline and analogues (monkey), 561
- Return of ovarian function, different doses of norethisterone oenanthate, 325
- Return of ovulation, after depot-medroxyprogesterone acetate, 1
- Return of ovulation and fertility, norethisterone oenanthate, 447
- RU 486 (17 β -hydroxy-11 β -(4-dimethylaminophenyl)-17 α -(1-propynyl)estra-4,9-dien-3-one)
- Scanning electron microscopy, multifilament IUD string, 215
- Second trimester abortion,
 - intraamniotic PGF_{2 α} , 171
 - intracervical PGE₂ gel, 171
- Semen characteristics, effect of copper intravas device (monkey), 45
- Semen quality, effect of phenoxybenzamine, 479
- Semen volume, effect of phenoxybenzamine, 479
- Seminal vesicles weight,
 - effect of LHRH antagonist (rat, rabbit), 271
 - effect of phenoxybenzamine hydrochloride (rat), 189
 - effect of 1,2,3-trihydroxypropane (rat), 291
- Seminiferous tubular function, effects of LHRH agonists, 163
- Sertoli cell function, effect of gossypol acetic acid (rat), 471
- Sexual behavior, effect of phenoxybenzamine hydrochloride (rat), 189
- SHBG (sex hormone binding globulin)

- SHBG capacity,
 - effect of ethinylestradiol + levonorgestrel, 305
 - effect of progestins administered alone and in combination with ethinyl estradiol, 261
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
- Sialic acid level, effect of norethisterone enanthate, 573
- Side effects,
 - depot-medroxyprogesterone acetate, 241
 - effect of levonorgestrel-releasing intracervical device, 31
 - intraamniotic instillation of PGF_{2α}, 171
 - intracervical administration of PGE₂ gel, 171
 - IUD, 241
 - levonorgestrel-releasing implant, 335
 - oral contraceptives, 241
 - prostaglandin treatment at home, 423
 - prostaglandin treatment in hospital, 423
 - RU 486 for termination of very early pregnancy, 399
 - SI-1435-releasing intracervical device, 411
 - ICu-380-Ag, 335
 - vacuum aspiration, 423
- Side effects and symptoms, 16,16-dimethyl-trans-Δ²PGE₁ methyl ester, 251, 457
- Sodium concentration in secreted testicular fluid, effect of gossypol acetic acid (rat), 471
- Species differences in sensitivity to antitesticular effects, [Ac-D-NAL(2)¹, 4FD-Phe², D-Trp³, D-Arg⁶]-LHRH (mouse, rat, rabbit, monkey) 271
- Species specific effects, use of LHRH antagonist (mouse, rat, rabbit, monkey), 283
- Sperm concentration, effect of phenoxybenzamine, 479
- Sperm count, effect of copper intravas device (monkey), 45
- Sperm motility, effect of copper intravas device (monkey), 45
- Sperm quality, effect of phenoxybenzamine hydrochloride (rat), 189
- Sperm transport, effect of phenoxybenzamine hydrochloride (rat), 189
- Spermatogenesis, effect of 1,2,3-trihydroxypropane (rat), 291
- Spinnbarkeit, effect of copper IUDs, 465
- SI-1435 (16-methylene-17α-acetoxy-19-nor-4-pregnene-3,20-dione)
- SI-1435 level, after insertion of SI-1435-releasing intracervical device, 411
- SI-1435-releasing intracervical contraceptive device,
 - clinical performance, 411
 - effects on pituitary and ovarian function, 411
- Subcutaneous administration of levonorgestrel, plasma levels and progestational activity (dog), 345
- Sulphated polysaccharide,
 - excretion after intra-vaginal administration (rabbit), 375
 - extent of vaginal absorption (rabbit), 375
 - plasma levels after intra-vaginal administration (rabbit), 375
 - tissue levels after intra-vaginal administration (rabbit), 375
- Surgical time required, comparison of tubal sterilization methods, '55
- ICu 220C, clinical experience, 229
- ICu 380Ag, clinical experience, 229, 335

CONTRACEPTION

- Termination rate,
 - levonorgestrel-releasing implant, 335
 - Mahua ring, 229
 - ICu 220C, 229
 - ICu 380Ag, 229, 335
- Testes weight,
 - effect of LHRH antagonist (rat, rabbit), 271
 - effect of phenoxybenzamine hydrochloride (rat), 189
 - effect of 1,2,3,-trihydroxypropane (rat), 291
- Testicular fluid secretion, effect of gossypol acetic acid (rat), 471
- Testis,
 - effect of gossypol acetic acid (rat), 471
 - effect of 1,2,3-trihydroxypropane (rat), 291
- Testosterone level,
 - effect of copper intravas device (monkey), 45
 - effect of ethinylestradiol + levonorgestrel, 305
 - effect of LHRH antagonist (mouse, rat, rabbit, monkey), 271
 - effect of phenoxybenzamine, 479
 - effect of phenoxybenzamine hydrochloride (rat), 189
 - effect of 1,2,3-trihydroxypropane (rat), 291
 - effect of triphasic ethinylestradiol + levonorgestrel, 305
- Testosterone secretion, effect of gossypol acetic acid on isolated interstitial cells (rat), 543
- Tetracycline hydrochloride,
 - effect of intrauterine administration (monkey), 561
 - effect of intrauteine instillation on uterine morphology (rat), 553
- Tetracycline level, following intrauterine administration of tetracycline (monkey), 561
- Tissue level, intra-vaginal administration of sulphated polysaccharide (rabbit), 375
- Toxicity studies [Ac-D-NAL(2)¹,4FD-Phe²,D-Trp³,D-Arg⁶]-LHRH (mouse, rat, rabbit, monkey), 283
- 1,2,3-Trihydroxypropane, effect on male fertility (rat), 291
- Trimethoprim, effect of intrauterine instillation on uterine morphology (rat), 553
- Triphasic ethinylestradiol + levonorgestrel, effect on ovarian function, 305
- Trophoblast, effect of β -momorcharin (mouse), 91
- Tubal sterilization, comparison of laparoscopy, culdoscopy and minilaparotomy, 55
- Tubectomized women, presence of autoantibodies to zona pellucida, 75
- Used cervical caps, recovery profile, 527
- Uterine acid phosphatase activity, effect of Hibiscus rosa-senensis benzene extract (mouse), 385
- Uterine alkaline phosphatase activity, effect of Hibiscus rosa-senensis benzene extract (mouse), 385
- Uterine cavity, measurements, 495
- Uterine damage,
 - effect of intrauterine quinacrine and related drugs (rat), 553
 - effect of intrauterine tetracycline and related drugs (rat), 553

- Uterine morphology,
 - effect of intrauterine instillation of quinacrine and analogues (rat), 553
 - effect of intrauterine instillation of tetracycline and analogues (rat), 553
- Uterine progesterone uptake, effect of Hibiscus rosa-senensis benzene extract (mouse), 385
- Uterine protein content, effect of Hibiscus rosa-senensis benzene extract (mouse), 385
- Uterine sound length, in vivo measurements of uterine cavities with the Cavimeter, 495
- Uterine weight, effect of Hibiscus rosa-senensis benzene extract (mouse), 385
- Vacuum aspiration, use of 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester for cervical dilatation, 251, 457
- Vacuum aspiration compared with prostaglandin treatment in hospital or at home, termination of early pregnancy, 423
- Vaginal absorption, sulphated polysaccharide (rabbit), 375
- Vaginal contraceptive suppository, A-gen 53®, 375
- Vaginal pill contraceptive, mestranol + norethindrone, 197
- Ventral prostate weight, effect of LHRH antagonist (rat, rabbit), 271
- Viability, effect of gossypol acetic acid on isolated interstitial cells (rat), 543
- Vimule®, examination of used caps, 527
- Weight, follow-up of children whose mothers used oral contraceptives prior to conception, 203
- Zinc level, use of copper intravas device (monkey), 45
- Zona pellucida autoantibodies, presence in tubectomized women, 75